Receptor for advanced glycation end products is overexpressed in psoriatic plaques independent of disease severity

Ozkay Ozgor, Gulsen Akoglu¹, Nuran Sungu², Eda Karaismailoglu³, Akin Aktas¹

Departments of Dermatology, ¹Dermatovenereology and ²Pathology, Ankara Ataturk Training and Research Hospital, ³Department of Biostatistics, Kastamonu University School of Medicine, Kastamonu, Turkey

Abstract

Background: Enhanced expression and excitation of the receptor for advanced glycation end products is considered to play a role in the regulation of many pro-inflammatory genes involved in the pathogenesis of psoriasis.

Aim: We investigated the expression of receptor for advanced glycation end product in various cell types, in lesional and peri-lesional skin of patients with psoriasis, and its correlation with disease severity.

Methods: Paraffin-embedded punch biopsy tissue taken from psoriatic plaques and peri-lesional normal appearing skin tissue of twenty patients with psoriasis, and normal skin samples of eleven healthy participants, were enrolled in the study. The sections were stained immunohistochemically with anti-receptor for advanced glycation end product antibody. The intensity of receptor for advanced glycation end product expression was assessed semi-quantitatively on epidermal cells, microvascular endothelium, dermal fibroblasts and inflammatory cells. They were graded as follows: 0 (no staining), 1 (weak), 2 (moderate) and 3 (strong) intensity.

Results: Receptor for advanced glycation end product expression on epidermis, microvascular endothelium, inflammatory cells and fibroblasts in the psoriatic plaques was more intense than perilesional and normal tissue (all P < 0.05). It did not correlate with disease severity.

Limitations: The main limitation of our study is that this was a semi-quantitative assessment, detected immunohistochemically in skin biopsies.

Conclusion: Receptor for advanced glycation end product expression may have an important role in psoriasis pathogenesis, independent of disease severity.

Key words: Immunohistochemistry, pathogenesis, psoriasis, receptor for advanced glycation end products

Introduction

Psoriasis is a multifactorial, chronic inflammatory skin disease, associated with complex interactions of various types of cells in the epidermis and dermis. The exact etiopathogenesis of psoriasis is still not clear.

The receptor for advanced glycation end products is a multiligand receptor. It has many ligands such as advanced glycation end products, high-mobility group box protein 1, S100/calgranulin, beta amyloid, phosphatidylserine, C3a and advanced oxidation protein products.¹ These are produced by various inflammatory cells. After ligand-receptor interaction, signal transduction affects many important pro-inflammatory pathways, resulting in a chronic inflammatory state.² The interaction of receptor for advanced glycation end product and its ligands activates many kinases, such as extracellular signal-regulated kinases 1 and 2, phosphatidylinositol-3 kinase, mitogen-activated protein kinases, stress-activated protein kinase/c-Jun N-terminal kinase and Janus kinases.³ Subsequently, various transcription factors, especially NF-κB, are activated to promote the inflammation processes. Receptor for advanced glycation end product expression is constitutively expressed in

How to cite this article: Ozgor O, Akoglu G, Sungu N, Karaismailoglu E, Aktas A. Receptor for advanced glycation end products is overexpressed in psoriatic plaques independent of disease severity. Indian J Dermatol Venereol Leprol 2017;83:556-60.

Received: August, 2016. Accepted: December, 2016.

Access this article online

Quick Response Code: Website: www.ijdvl.com

DOI: 10.4103/ijdvl.IJDVL_718_16

© 2017 Indian Journal of Dermatology, Venereology, and Leprology | Published by Wolters Kluwer - Medknow
different cell types, and its ligands and inflammatory mediators induce its overexpression. Pro-inflammatory consequences of this activation are hyperproliferation, immune system activation, lymphocyte infiltration into the epidermis and cytokine induction, all of which are observed in psoriasis pathogenesis. We were unable to find any previous reports about the expression profile of receptor for advanced glycation end product in different types of cells in psoriatic plaques compared with normal skin in healthy participants.

The present study aimed (i) to evaluate the presence of receptor for advanced glycation end product expression on epidermal, endothelial, inflammatory cells and fibroblasts in lesional and peri-lesional skin of patients with psoriasis, (ii) to compare the intensity of its expression between patients with psoriasis and healthy participants and (iii) to investigate the relation between the intensity of its expression and disease severity.

Methods

Subjects

Twenty patients who were clinically and histopathologically diagnosed as having chronic plaque psoriasis in the dermatology outpatient clinic of Ankara Ataturk Training and Research Hospital, were enrolled in this prospective study. Patients included were not on topical therapy for at least two weeks, and not on systemic or phototherapy for the last six months. The demographic and clinical data of the patients including age, gender, age of onset, disease duration, psoriasis area and severity index scores, and previous treatments were noted. The control group constituted of eight healthy women who underwent mammoplasty and three men. The controls were matched with patients according to age and gender. None of the patients or controls were younger than eighteen, obese, or had a history of smoking. The controls did not have any systemic illness, were not on any medication, and had no history of alcohol intake. The women were not pregnant or lactating.

Four millimeter punch biopsies from psoriatic plaques and peri-lesional skin (2 cm away from psoriatic plaques) were obtained from sun-protected regions. The biopsy specimens of the control group were taken from sun-protected body regions. The study was approved by the hospital ethics committee, and all participants signed the informed consent form.

Evaluation of Immunoreactivity

The epidermis, inflammatory cells (lymphocytes), microvascular endothelial cells and fibroblasts were examined for receptor for advanced glycation end product expression. To evaluate this, semi-quantitative analysis with a scale ranging from no staining (0), weak (1), moderate (2) to strong (3) intensity was performed in the biopsy specimen as described in detail in this reference. Dermal fibroblasts were identified as spindle cells with a clear separation from vessels.

Statistical analysis

Evaluation of normality was performed with the Shapiro–Wilk test. Wilcoxon test was performed for comparing receptor for advanced glycation end product expression intensity of lesional and peri-lesional skin samples. Spearman correlation test was used to analyze correlation between receptor for advanced glycation end product intensity and clinical features of patients. $P < 0.05$ was considered statistically significant. All statistical analyses were performed using SPSS version 15.0 statistical software package (SPSS Inc., Chicago, IL, USA).

Results

The study included twenty patients with psoriasis (ten women and ten men) and eleven healthy controls matched for gender and age (eight women and three men). Table 1 presents the demographic characteristics of the study population. Figures 1-3 show staining scores for receptor for advanced glycation end product in lesional and peri-lesional skin samples of patients with psoriasis, and comparison with controls.

As shown in Table 2, the intensity of receptor for advanced glycation end product expression in the epidermis, microvascular endothelial cells, inflammatory cells and fibroblasts in psoriatic

| Demographic characteristics | Patients with psoriasis ($n=20$) | Controls ($n=11$) | $P$ |
|----------------------------|---------------------------------|-----------------|-----|
| Age (years)                | 40.35±12.04                     | 43.91±10.39     | 0.416|
| Gender, female, n (%)      | 10 (50.0)                       | 8 (72.7)        | 0.275|
| Onset age of psoriasis (years) | 40.35±12.04                     | -               | -   |
| Disease duration (months)  | 39.65±30.08                     | -               | -   |
| PASI                       | 10.75±7.56                      | -               | -   |
| Previous treatments        |                                 |                 |     |
| No therapy                 | 8 (40.0)                        | -               | -   |
| Topical                    | 12 (60.0)                       | -               | -   |
| Systemic                   | -                               | -               |     |
| Phototherapy               | -                               | -               |     |

*Values are given as mean±SD. SD: Standard deviation, PASI: Psoriasis area and severity index.

Figure 1: Control, score: 0 (RAGE, ×400)
plaques of patients was significantly higher than their peri-lesional counterparts (all \( P < 0.05 \)). The intensity of expression in all these cell types was stronger in lesional samples than those of healthy controls (all \( P < 0.05 \)) [Table 3]. The peri-lesional skin of patients did not have different expression levels in the epidermis, microvascular endothelial cells and fibroblasts (all \( P > 0.05 \)), except for inflammatory cells, when compared with controls [Table 4]. The intensity of receptor for advanced glycation end product expression in the inflammatory cells of peri-lesional skin of patients was weaker than healthy controls (\( P = 0.001 \)). Statistical analysis did not show any correlation between the intensity of expression in lesional and peri-lesional tissue with respect to the patients’ age, gender, disease duration, age of onset or disease severity (all \( P > 0.05 \)).

**Discussion**

The skin and lung are unique regions, in which the receptor for advanced glycation end product expression is high throughout life.\(^7,8\) Pathologically upregulated expression is demonstrated in diabetics, patients with chronic inflammatory disorders including Alzheimer’s disease, atherosclerosis, malignancies and in ageing.\(^5,8\) Furthermore, it was found to be overexpressed in psoriatic epidermis,\(^9\) sun-exposed skin,\(^5\) on the reticular dermis, extracellular matrix of patients with localized systemic sclerosis and calcinosis, which suggested its possible contribution in inflammatory skin disorders.\(^5\)

This is the first study that demonstrates the overexpression of receptor for advanced glycation end product in various cell types that are involved in psoriasis pathogenesis. Epidermal, microvascular endothelial, inflammatory cells and fibroblasts showed more intense expression in psoriatic plaques than the normal-appearing skin of patients and healthy controls. It is shown to work as an adhesion molecule for leukocytes as it interacts with leukocyte beta-2 integrin Mac-1.\(^10\) Psoriasin (S100A7) induces oxidative stress in both endothelial and epithelial cells, acting through receptor for advanced glycation end products.\(^11\) Ligand-receptor for advanced glycation end product interactions induce several signal pathways, including NF-kB, which is suggested to be involved in the pathogenesis of psoriasis. Activation of NF-kB results in the release of pro-inflammatory cytokines, cell adhesion molecules, metalloproteinases and regulates immune system cells.\(^1,3,5\) Activated NF-kB binds to the promoter region of receptor for advanced glycation end product in the nucleus, and enhances its expression as well as inhibits glyoxalase 1 expression. This results in the upregulation of advanced glycation end product formation.\(^1,5\) NF-kB activation is considered to be an important link between the innate and adaptive immune system.\(^1,1\) The consequence of this process leads to the sustained activation of NF-kB.\(^1,9\) The major impact of receptor for advanced glycation end product signaling is considered to be the conversion of a transient cellular stimulation into a sustained cellular dysfunction, and a prolonged inflammatory response.\(^1,3\) Our findings point to the possible essential role of receptor for advanced glycation end product activation, affecting many cell types in psoriasis.

**Table 2: Comparison of receptor for advanced glycation end products expression intensity in lesional and peri-lesional skin samples of patients with psoriasis *\)**

| Expression intensity of RAGE | Lesional skin (n=20) | Perilesional skin (n=20) | \( P \) |
|-----------------------------|---------------------|------------------------|------|
| Epidermis                   | 2.0 (2-3)           | 2.0 (1-2)              | 0.002|
| Inflammatory cells          | 2.5 (2-3)           | 0 (0-2)                | <0.001|
| Microvascular endothelial cells | 2.5 (2-3)     | 2.0 (1-2)              | 0.001|
| Fibroblasts                 | 2.5 (2-3)           | 2.0 (1-2)              | <0.001|

*Values are given as median (minimum–maximum). RAGE: Receptor for advanced glycation end products

**Table 3: Comparison of receptor for advanced glycation end products expression intensity in lesional skin of patients with psoriasis, and normal skin samples of controls*\)**

| Expression intensity of RAGE | Lesional skin of patients (n=20) | Normal skin of controls (n=11) | \( P \) |
|-----------------------------|----------------------------------|------------------------------|------|
| Epidermis                   | 2.0 (2-3)                       | 2.0 (1-3)                    | 0.015|
| Inflammatory cells          | 2.5 (2-3)                       | 2.0 (1-3)                    | 0.009|
| Microvascular endothelial cells | 2.5 (2-3)          | 2.0 (1-3)                    | 0.015|
| Fibroblasts                 | 2.5 (2-3)                       | 2.0 (1-2)                    | 0.001|

*Values are given as median (minimum–maximum). RAGE: Receptor for advanced glycation end products

**Figure 2: Strong staining for receptor for advanced glycation end product (score: 3) on microvascular endothelium (red arrow) and inflammatory cells (yellow arrow) in the lesional skin of the same patient (RAGE, \( \times 200 \))**

**Figure 3: Strong staining for receptor for advanced glycation end product (score: 3) on microvascular endothelium (red arrow), inflammatory cells (yellow arrow) and fibroblasts (white arrow) in the lesional skin of the same patient (RAGE, \( \times 200 \))**
The pattern recognition receptor (RAGE) is a counterreceptor for advanced glycation end product ligands, which stimulate receptor for advanced glycation end product expression on inflammatory cells and fibroblasts suggests that many cell types involved in psoriatic plaques have overproduced receptor for advanced glycation end product. We detected that the receptor for advanced glycation end product expression on inflammatory cells in the normal peri-lesional skin was weaker than those in the normal skin of healthy participants. We may consider that the psoriatic plaques have overproduced receptor for advanced glycation end product ligands, which stimulate receptor for advanced glycation end product overexpression more than the peri-lesional normal skin surrounding the plaques. Therefore, a relative downregulation of expression may occur. Some mediators working against the inflammatory process may have been involved in the adjacent peri-lesional skin to limit the inflammation of the psoriatic plaque. As psoriatic inflammation progresses, circulating inflammatory cells with higher receptor for advanced glycation end product expression may home to the skin adjacent to the psoriatic lesion, causing expansion of the plaque or development of new plaques. Further studies are needed to investigate and confirm our observations.

The limitation of our study is the semi-quantitative assessment of receptor for advanced glycation end product expression in skin biopsies. Although the results of our analysis need to be quantitatively verified, our results demonstrate the potential role of receptor for advanced glycation end product overexpression in the pathogenesis of psoriasis.

**Conclusion**

Receptor for advanced glycation end product expression may have an important role in psoriasis pathogenesis, independent of disease severity. Further studies are needed to detect the triggers that lead to overexpression and subsequent activation of these pathways. Future studies may study this as a potential target in therapy of psoriasis.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signaling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013;25:2185-97.

2. Yan SF, Yan SD, Ramasamy R, Schmidt AM. Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med 2009;41:408-22.

3. Glogkolou P, Böhm M. Advanced glycation end products: Key players in skin aging? Dermatoendocrinol 2012;4:259-70.

4. Soboleva AG, Bruskin SA, Nikolaev AA, Sobolev VV, Mezentsev AV. Role of receptor for advanced glycation end-products in pathogenesis of psoriasis. Mol Biol (Mosk) 2013;47:743-53.

5. Lohwasser C, Neureiter D, Weigle B, Kirchner T, Schuppan D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006;126:291-9.

6. Davies CA, Herrick AL, Cordingley L, Freemont AJ, Jeziorska M. Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis. Rheumatology (Oxford) 2009;48:876-82.

7. Bret J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699-712.

8. Chuaa YK, Basir R, Talib H, Tie TH, Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam 2013;2013:403460.

9. Sakaguchi M, Murata H, Aoyama Y, Hibino T, Putranto EW, Ruma IM, et al. DNAX-activating protein 10 (DAP10) membrane adaptor associates with receptor for advanced glycation end products (RAGE) and modulates the RAGE-triggered signaling pathway in human keratinocytes. J Biol Chem 2014;289:23389-402.

10. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 2003;198:1507-15.

11. Shubbar E, Vegfors J, Carlström M, Petersson S, Enerbäck C.
Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Res Treat 2012;134:71-80.

12. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010;59:249-55.

13. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.

14. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792-808.

15. Riehl A, Bauer T, Brors B, Busch H, Mark R, Németh J, et al. Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation. BMC Genomics 2010;11:537.

16. Wolf R, Mascia F, Dharamsi A, Howard OM, Cataisson C, Bliskovski V, et al. Gene from a psoriasis susceptibility locus primes the skin for inflammation. Sci Transl Med 2010;2(61):61ra90.

17. Damasiewicz-Bodzek A, Wielkoszynski T. Advanced protein glycation in psoriasis. J Eur Acad Dermatol Venereol 2012;26:172-9.